K. Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
K. Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anthony T. Papenfuss
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
2 shared publications - Bhupinder Pal
School of Cancer Medicine, La Trobe University, Bundoora VIC 3086, Australia
2 shared publications - Daniel L. Cameron
Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic 3052, Australia
2 shared publications - Dawn S. Lin
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
2 shared publications - Delphine Merino
Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
2 shared publications - François Vaillant
ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
2 shared publications
Latest Publications
- Open Access
- 24 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1945
Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer
The original version of this Article contained an error in Fig. 4. In the left histogram of the right panel of Fig. 4d, several data points were inadvertently deleted from the histogram during the production process. This error has been corrected in both the PDF and HTML versions of the Article. The original, incorrect version of Fig. 4 is presented in the accompanying Publisher Correction.
- 24 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1945
Open AccessPublisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer
The original version of this Article contained an error in Fig. 4. In the left histogram of the right panel of Fig. 4d, several data points were inadvertently deleted from the histogram during the production process. This error has been corrected in both the PDF and HTML versions of the Article. The original, incorrect version of Fig. 4 is presented in the accompanying Publisher Correction.
- Open Access
- 15 February 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-12
Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer
Primary triple negative breast cancers (TNBC) are prone to dissemination but sub-clonal relationships between tumors and resulting metastases are poorly understood. Here we use cellular barcoding of two treatment-naïve TNBC patient-derived xenografts (PDXs) to track the spatio-temporal fate of thousands of barcoded clones in primary tumors, and their metastases. Tumor resection had a major impact on reducing clonal diversity in secondary sites, indicating that most disseminated tumor cells lacked the capacity to ‘seed’, hence originated from ‘shedders’ that did not persist. The few clones that continued to grow after resection i.e. ‘seeders’, did not correlate in frequency with their parental clones in primary tumors. Cisplatin treatment of one BRCA1-mutated PDX model to non-palpable levels had a surprisingly minor impact on clonal diversity in the relapsed tumor yet purged 50% of distal clones. Therefore, clonal features of shedding, seeding and drug resistance are important factors to consider for the design of therapeutic strategies.
- 15 February 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-12
Open AccessBarcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer
Primary triple negative breast cancers (TNBC) are prone to dissemination but sub-clonal relationships between tumors and resulting metastases are poorly understood. Here we use cellular barcoding of two treatment-naïve TNBC patient-derived xenografts (PDXs) to track the spatio-temporal fate of thousands of barcoded clones in primary tumors, and their metastases. Tumor resection had a major impact on reducing clonal diversity in secondary sites, indicating that most disseminated tumor cells lacked the capacity to ‘seed’, hence originated from ‘shedders’ that did not persist. The few clones that continued to grow after resection i.e. ‘seeders’, did not correlate in frequency with their parental clones in primary tumors. Cisplatin treatment of one BRCA1-mutated PDX model to non-palpable levels had a surprisingly minor impact on clonal diversity in the relapsed tumor yet purged 50% of distal clones. Therefore, clonal features of shedding, seeding and drug resistance are important factors to consider for the design of therapeutic strategies.